Synthesis of Oxindoles and Benzofuranones *via* Oxidation of 2-Heterocyclic BMIDAs

Ciaran P. Seath
James W. B. Fyfe
John J. Molloy
Allan J. B. Watson*

Department of Pure and Applied Chemistry, WestCHEM,
University of Strathclyde, 295 Cathedral St., Glasgow, G1 1XL,
UK.

allan.watson.100@strath.ac.uk

Received:
Accepted:
Published online:
DOI:

Abstract: The synthesis of functionalized oxindoles and benzofuranones *via* oxidation of 2-BMIDA indoles and benzofurans, respectively, is described. Interconversion of boron species (BMIDA $\rightarrow$ BF₃K) was necessary to enable oxidation and overcome boronic acid stability issues associated with a difficult BMIDA hydrolysis. Overall, a robust process was developed that allowed access to a small library of oxindole and benzofuranone products and facilitated the step-efficient synthesis of biologically-active compounds containing the oxindole pharmacophore.

Key words: Boron, oxidation, heterocycles, lactams, lactones

The oxindole motif is present in the core of numerous biologically active natural products as well as pharmaceuticals such as tenidap, coreulescine, and semaxanib (Figure 1).¹ Consequently, numerous methods have been and continue to be developed to allow access to this privileged chemotype.

Figure 1 Pharmaceutically relevant oxindoles.

The most common synthetic approaches towards the oxindole framework forge the pyrrole nucleus either *via* disconnection at the amide C-N bond to provide a phenylacetic acid precursor,² or at the C-3 position to afford an anilide precursor (Scheme 1a).³ Despite significant research, preparation of oxindoles beginning from the corresponding indole starting materials are comparatively limited,⁴ with oxidative methods often suffering from the problem of over-oxidation to deliver isatins (Scheme

1b).⁵ Hydrolysis of 2-oxy-indoles gives the corresponding oxindoles; however, this requires a pre-oxygenated indole as a starting material (Scheme 1c).⁶ We recently disclosed a one-pot synthesis of 2-heterocyclic BMIDA's,⁷ which are bench stable, free flowing solids that can be stored indefinitely without degradation.⁸ Here we present the utility of 2-BMIDA indoles and benzofurans as readily accessible precursors to oxindoles and benzofuranones, respectively, and the scope and limitations of this process (Scheme 1d).

Scheme 1 Methods for the synthesis of oxindoles.

Oxidation of 2-borylated indoles is limited to two single examples using two specific 2-BPin indole substrates.⁹ This class of compounds is generally difficult to access/handle due to issues with protodeboronation.¹⁰ Consequently, a BMIDA-based process would offer significant synthetic advantages due to the accessibility and stability of these organoboron derivatives.⁸

Our initial studies commenced with *N*-Ts-indole-2-BMIDA **1**, using well-established Brown-type reaction conditions: H₂O₂ in

a range of solvent/water mixtures and in the presence of base (Scheme 2 – see Supporting Information for full details).¹¹

Scheme 2 Attempted direct hydrolysis/oxidation of 2-BMIDA indole **1**. PDB = protodeboronation.

Based on the base lability of BMIDA and the well studied slow or fast release of the parent boronic acid,¹⁰ we planned an *in situ* hydrolysis of **1** to deliver **2** that would then be oxidized to deliver **3a**. To our surprise, when using a base/oxidant system of NaOH/H₂O₂ at room temperature (fast hydrolysis conditions), the BMIDA group remained intact, *i.e.* no hydrolysis was observed, even in the presence of excess aq. NaOH. In an attempt to drive the hydrolysis step, the reaction was heated to 50 °C with increasing quantities of NaOH. However, while hydrolysis could be induced, these reactions returned the protodeboronated product **4** in quantitative yields in all cases, presumably due to the sensitivity of **2** under these reaction conditions. Attempting to temper the reaction conditions using a slow hydrolysis protocol with either K₃PO₄ or K₂CO₃ in the presence of H₂O₂ returned starting material (**1**) only. Changing the oxidant to Oxone® had a small positive effect – hydrolysis remained sluggish, requiring extended reaction times or elevated temperatures and although trace quantities of **3a** were observed under these conditions, protodeboronation product **4** dominated along with degradation of **3a**.

These initial investigations highlighted a compatibility issue between the conditions required to hydrolyze the BMIDA unit and the stability of the intermediate boronic acid (as well as the oxindole product). To overcome these issues, we postulated that a simple boron species interconversion process might be achieved under mild reaction conditions to deliver an organoboron derivative that could then be oxidized under conditions sufficiently mild to inhibit degradation of the organoboron intermediate or product. In particular, BMIDA species can be converted to the potassium organotrifluoroborate (BF₃K) derivative under relatively mild reaction conditions¹² and BF₃K species can also be oxidized under mild conditions.¹³ However, BMIDA-BF₃K interconversion on this template was unknown. Accordingly, we evaluated conversion of BMIDA **1** to the BF₃K derivative **5**.

Scheme 3 Conversion of BMIDA **1** to BF₃K **5**.

A short survey of reaction conditions found that **1** could be quantitatively converted to **5** upon treatment with aq. KHF₂ in MeOH at 70 °C (Scheme 3a). In addition, **5** could be quantitatively converted to the desired oxindole product **3a** using Oxone®. Combining these two events proved to be straightforward (Table 1). Oxidation of intermediate **5** was found to be sluggish in MeOH; however, a solvent switch to acetone before addition of the oxidant was more effective (entry 1 vs. entry 2). A short optimization of reaction time and KHF₂ stoichiometry (entries 2–5) revealed that the overall two-step process could be completed in 6 hours using 5 equiv. of KHF₂ to facilitate conversion to **5**, ultimately delivering 99% conversion to **3a**. Interestingly, while oxidation of the intermediate BF₃K **5** was facile with Oxone®, NaBO₃ and H₂O₂ were ineffective for oxidation of this intermediate (entries 6 and 7, respectively).

Table 1 Oxidation of Indole BMIDA *via* speciation

Entry	Conditions	3a (%) ^a
1	aq. KHF ₂ (3 eq), 2 h/ Oxone®, 18 h ^b	27
2	aq. KHF ₂ (3 eq), 2 h/ Oxone®, 18 h ^c	44
3	aq. KHF ₂ (5 eq), 2 h/ Oxone®, 18 h ^c	92
4	aq. KHF ₂ (5 eq), 4 h/ Oxone®, 18 h ^c	99
5	aq. KHF ₂ (5 eq), 4 h/ Oxone®, 2 h ^c	99
6	aq. KHF ₂ (5 eq), 4 h/ NaBO ₃ , 4 h ^c	0
7	aq. KHF ₂ (5 eq), 4 h/ H ₂ O ₂ , 4 h ^c	0

^aDetermined by HPLC analysis against an internal standard. ^bOxidant added directly. ^cSolvent switch to acetone before addition of Oxidant.

With optimum conditions in hand, the scope of the reaction was investigated by application to a range of substituted 2-BMIDA indole architectures (Scheme 4).

Scheme 4 Substrate scope of the oxidation process. Isolated yields.

^aDetermined by ¹H NMR analysis.

The reaction was found to be tolerant of both electron-donating and electron-withdrawing groups (**3g**, **3h**, **3i**). Halogenated substrates were also effective, providing a synthetic handle for

further functionalization (**3c**, **3d**, **3e**, **3f**). In addition, azaindoline **3j** was delivered in moderate yield by NMR (42%) with the mass balance consisting of the product of protodeboronation. However, this product was found to be labile to hydrolysis on silica. The *N*-tosyl group could be replaced with a methyl unit but resulted in a decrease in yield of the corresponding oxindole (**3b**). Other *N*-protecting groups were not assessed. Lastly, in addition to oxindoles, the oxidation process was applicable to 2-BMIDA benzofurans to allow access to benzofuranones in excellent yields (**3k**, **3l**).

In keeping with our interests in medicinal chemistry,¹⁴ we sought to utilize the oxindole products as building blocks in the synthesis of biologically active molecules. In particular, the ubiquity of the oxindole motif in kinase drug discovery¹⁵ led us to target compounds of this class. First steps into derivatization of our oxindole products quickly identified an issue with deprotection of the *N*-tosyl. Specifically, the lactam was found to be readily hydrolyzed under both acidic and basic conditions.¹⁶ To the best of our knowledge, no methods exist for the deprotection of *N*-Ts-oxindole, although sulfonamides have been removed from C3-substituted oxindoles using several approaches.¹⁷ Accordingly, we surveyed reaction conditions commonly used for sulfonamide cleavage; however, neither NaOH or TBAF afforded any of the desired product **6** (Table 2 entries 1-3);^{17d} these conditions all resulted in hydrolysis of the lactam at room temperature.

Table 2 Deprotection of *N*-Ts oxindole **3a**.

Entry	Conditions	6 (%) ^a
1	6 M NaOH, 1,4-dioxane, rt	0
2	1 M NaOH, 1,4-dioxane, rt	0
3	1 M TBAF, THF, rt	0
4	Mg, MeOH, rt	0
5	Sml ₂ , pyrrolidine, H ₂ O, rt	0
6	Na, naphthalene, -78 °C	90

^aIsolated yields.

To limit exposure to basic reaction conditions, we evaluated several single-electron methods. Mg powder in MeOH resulted in solvolysis of **3a**.^{17b} Sml₂ conditions led to full consumption of the starting material within five minutes of addition; however, none of the desired oxindole was observed, delivering only an unidentifiable mixture of products.¹⁸ Fortunately, application of sodium naphthalenide at -78 °C provided clean conversion to the desired oxindole product in 90% isolated yield.¹⁹

With effective conditions for the deprotection now available, we were able to prepare several biologically active products (Scheme 5 and 6). Both the natural product (±)-coerulescine²⁰ and kinase inhibitor semaxanib²¹ could be quickly accessed through common oxindole **3a** following tosyl deprotection (Scheme 5). From this common intermediate, condensation with commercially available pyrrole **7** afforded semaxanib in excellent yield, while C3 alkylation followed by ring expansion²² enabled access to (±)-coerulescine in moderate overall yield. Although the dialkylation to form the cyclopropane proceeded with good conversion by NMR (*ca.* 60%), the desired spirocycle

8 was found to be highly unstable on silica, thereby limiting the yield of this process.

Scheme 5 Synthesis of semaxanib and (±)-coerulescine. Isolated yields.

Tenidap, a potent COX inhibitor,²³ was efficiently synthesized in five steps from oxindole **3e** (Scheme 6). Tosyl deprotection gave the free oxindole **9**, which, upon treatment with phenyl chloroformate followed by ammonium carbonate, gave oxindole **10** in 73% yield. Condensation with 2-thiophenecarbonyl chloride and subsequent exposure to ammonium carbonate afforded tenidap in excellent yield.

Scheme 6 Synthesis of tenidap. Isolated yields.

In conclusion, we have reported a novel method for the preparation of oxindoles from 2-BMIDA indoles. A boron species (BMIDA to BF₃K) interconversion was used to overcome the instability of the intermediate indole 2-boronic acid towards the conditions required for hydrolysis of an unusually robust BMIDA species. The BF₃K species was readily oxidized to the corresponding oxindole under mild conditions allowing one-pot access to oxindole products. The scope of the reaction was evaluated by application towards a series of substrates and further exemplified in the context of the synthesis of kinase inhibitors semaxanib and tenidap, and the natural product coerulescine.

The experimental section has no title; please leave this line here.

All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Where necessary, purification was carried out according to standard laboratory methods.²⁴ Reactions were carried out using conventional glassware (preparation of intermediates) or in capped 5 mL microwave vials. Room temperature was generally *ca.* 18 °C. Reactions were carried out at elevated temperatures using a temperature-regulated hotplate/stirrer. Thin layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analyzed under 254 nm UV light or developed using potassium permanganate solution. Normal phase flash chromatography was carried out using ZEOprep 60 HYD 40–63 µm silica gel. Fourier Transformed Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 machine. ¹⁹F NMR spectra were obtained on a Bruker AV 400 spectrometer at 376 MHz. ¹¹B NMR spectra were obtained on a Bruker AV 400 spectrometer at 128 MHz. ¹H and ¹³C NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 125 MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz with CDCl₃ referenced at 7.26 (¹H) and 77.0 ppm (¹³C) and DMSO-*d*₆ referenced at 2.50 (¹H) and 39.5 (¹³C). ¹¹B NMR spectra are referenced to BF₃•Et₂O. High-resolution mass spectra were obtained through analysis at the EPSRC UK National Mass Spectrometry Facility at Swansea University.

General Procedure – Oxidation products (Scheme 4).

An oven dried 10 mL microwave vial was charged with R-BMIDA (0.1 mmol, 1 equiv) before the addition of 4 mL MeOH. The vial was capped before the addition of KHF₂ (100 µL, 4.5 M aq. solution, 0.5 mmol, 5 equiv). The reaction was then heated to 70 °C for 4 h. At this point the reaction was cooled, vented, decapped, and the MeOH solution was transferred to a clean flask and concentrated under reduced pressure to provide a white solid. The residue was diluted with hot acetone and the BF₃K solution was transferred to a 5 mL flask (2×2 mL) and concentrated under reduced pressure. The resulting residue was diluted with 0.5 mL acetone before the addition of Oxone® (35 mg, 0.11 mmol, 1.1 equiv) in 0.5 mL H₂O. The reaction was left to stir for 2 h before the addition of 1 M HCl (2 mL). The reaction mixture was then diluted with water (2 mL) and extracted with CH₂Cl₂ (2×5 mL). The organics were filtered through 2 cm of silica gel and washed through with a further 20 mL CH₂Cl₂. The resulting solution was concentrated under vacuum to afford the desired product.

1-Tosylindolin-2-one (3a)

Prepared according to the general procedure from (1-tosyl-1*H*-indol-2-yl)boronic acid, MIDA ester (43 mg). Yield: 27 mg, 92%. Off-white amorphous solid.

IR (solid): 3092, 3058, 2962, 2947, 1768, 1595, 1478, 1465, 1377 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.91 (d, *J* = 8.3 Hz, 2H), 7.83 (d, *J* = 8.3 Hz, 1H), 7.29–7.20 (m, 3H), 7.13 (d, *J* = 7.4, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 3.47 (s, 2H), 2.34 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 172.3, 145.2, 139.9, 134.8, 129.3, 128.1, 127.5, 124.2, 124.1, 122.7, 113.2, 35.6, 21.2.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₅H₁₄NO₃S: 288.0689; found: 288.0690.

1-Methylindolin-2-one (3b)

Prepared according to the general procedure from (1-methyl-1*H*-indol-2-yl)boronic acid, MIDA ester (29 mg). Yield: 8 mg, 54%. Dark green liquid.

IR (solid): 3060, 2924, 2855, 1698, 1614, 1496, 1470, 1370, 1349 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.31–7.26 (m, 1H), 7.26–7.22 (m, 1H), 7.05 (dd, *J* = 7.5, 0.9 Hz, 1H), 6.82 (d, *J* = 7.8 Hz, 1H), 3.52 (s, 2H), 3.21 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 174.6, 144.7, 127.4, 123.8, 121.9, 107.6, 35.3, 25.7.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₉H₁₀NO: 148.0757; found: 148.0753.

6-Chloro-1-tosylindolin-2-one (3c)

Prepared according to the general procedure from (6-chloro-1-tosyl-1*H*-indol-2-yl)boronic acid, MIDA ester (46 mg). Yield: 29 mg, 90%. White amorphous solid.

IR (solid): 2924, 2857, 1768, 1610, 1595, 1424, 1372, 1333, 1236 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.07–7.88 (m, 3H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 1.1 Hz, 2H), 3.52 (s, 2H), 2.43 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 172.3, 146.0, 141.2, 135.0, 134.4, 129.9, 128.1, 125.5, 125.4, 124.7, 121.5, 114.4, 35.7, 21.7.

HRMS (TOF): *m/z* [M+H]⁺ calcd for C₁₅H₁₃ClNO₃S: 322.0305; found: 322.0304.

5-Fluoro-1-tosylindolin-2-one (3d)

Prepared according to the general procedure from (5-fluoro-1*H*-indol-2-yl)boronic acid, MIDA ester (44 mg). Yield: 28 mg, 92%. Off-white amorphous solid.

IR (solid): 3073, 2973, 2924, 1761, 1610, 1599, 1476, 1368 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.06–7.93 (m, 2H), 7.88 (dd, *J* = 9.0, 4.5 Hz, 1H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.04 (td, *J* = 9.0, 2.8 Hz, 1H), 6.98–6.94 (m, 1H), 3.55 (s, 2H), 2.43 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 172.3, 159.9 (d, ¹*J*_{C-F} = 244.0 Hz), 145.8, 135.1, 129.8, 128.0, 124.9 (d, ³*J*_{C-F} = 8.6 Hz), 115.1 (d, ²*J*_{C-F} = 23.3 Hz), 114.9 (d, ³*J*_{C-F} = 7.9 Hz), 112.4 (d, ²*J*_{C-F} = 24.9 Hz), 36.2, 21.7.

¹⁹F NMR (CDCl₃, 471 MHz): δ –117.57

HRMS (TOF): *m/z* [M+H]⁺ calcd for C₁₅H₁₂FNO₃S: 306.0600; found: 306.0602.

5-Chloro-1-tosylindolin-2-one (3e)

Prepared according to the general procedure from (5-chloro-1*H*-indol-2-yl)boronic acid, MIDA ester (46 mg). Yield: 29 mg, 90%. White amorphous solid.

IR (solid): 2956, 2922, 1755, 1599, 1470, 1370, 1232 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.99–7.94 (m, 2H), 7.86 (d, *J* = 8.8 Hz, 1H), 7.36–7.29 (m, 3H), 7.22–7.19 (m, 1H), 3.55 (s, 2H), 2.43 (s, 3H).

¹³C NMR (DMSO-*d*₆, 101 MHz): δ 172.0, 145.9, 138.9, 135.0, 130.2, 129.8, 128.6, 128.0, 125.0, 124.9, 114.8, 35.9, 21.7.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₅H₁₃ClNO₃S: 322.0299; found: 322.0302.

5-Bromo-1-tosylindolin-2-one (3f)

Prepared according to the general procedure from (5-bromo-1-tosyl-1*H*-indol-2-yl)boronic acid, MIDA ester (51 mg). Yield: 24 mg, 66%. Light brown amorphous solid.

IR (solid): 3088, 2958, 2924, 2854, 1757, 1599, 1469, 1455, 1375 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.01–7.96 (m, 2H), 7.83 (d, *J* = 8.8 Hz, 1H), 7.51–7.46 (m, 1H), 7.39–7.33 (m, 3H), 3.58 (s, 2H), 2.45 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 171.4, 145.5, 138.9, 134.4, 131.0, 129.4, 127.5, 127.4, 124.7, 117.2, 114.7, 35.3, 21.3.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₅H₁₃BrN₁O₃S₁: 365.9794; found: 365.9798.

5-Methoxy-1-tosylindolin-2-one (3g)

Prepared according to the general procedure from (5-methoxy-1*H*-indol-2-yl)boronic acid, MIDA ester (46 mg). Yield: 28 mg, 88%. Light brown amorphous solid.

IR (solid): 2950, 2924, 2855, 1757, 1601, 1483, 1470, 1372 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.97 (d, *J* = 8.3 Hz, 2H), 7.82 (d, *J* = 9.0 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 2H), 6.85 (dd, *J* = 9.0, 2.4 Hz, 1H), 6.79 (s, 1H), 3.79 (s, 3H), 3.53 (s, 2H), 2.42 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 172.7, 157.0, 145.6, 135.2, 133.8, 129.8, 127.9, 124.5, 114.5, 113.2, 111.2, 55.7, 36.5, 21.7.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₆H₁₆NO₄S: 318.0795; found: 318.0796.

1-Tosyl-5-(trifluoromethoxy)indolin-2-one (3h)

Prepared according to the general procedure from (1-tosyl-5-(trifluoromethoxy)-1*H*-indol-2-yl)boronic acid, MIDA ester (51 mg). Yield: 30 mg, 80%. Off-white amorphous solid.

IR (solid): 2958, 2928, 2857, 1761, 1601, 1480, 1374 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.91 (d, *J* = 8.3 Hz, 2H), 7.87 (d, *J* = 8.9 Hz, 1H), 7.27 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 8.9 Hz, 1H), 7.04 (s, 1H), 3.51 (s, 2H), 2.36 (s, 3H).

¹³C NMR (CDCl₃, 126 MHz): δ 172.0, 146.0, 138.9, 135.0, 129.9, 128.1, 124.8, 121.6, 119.4, 118.2, 114.7, 36.1, 21.7. Trifluoromethyl carbon not observed.

¹⁹F NMR (CDCl₃, 471 MHz): δ -58.21.

HRMS (TOF): *m/z* [M+H]⁺ calcd for C₁₆H₁₂F₃NO₄S: 372.0517; found: 372.0527.

Methyl 2-oxo-1-tosylindoline-5-carboxylate (3i)

Prepared according to the general procedure from (5-(methoxycarbonyl)-1-tosyl-1*H*-indol-2-yl)boronic acid, MIDA ester (48 mg). Yield: 22 mg, 62%. White amorphous solid.

IR (solid): 2956, 2924, 2855, 1766, 1711, 1623, 1601, 1483, 1450, 1374 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.98 (d, *J* = 8.6 Hz, 1H), 7.92 (d, *J* = 7.0 Hz, 3H), 7.83 (s, 1H), 7.27 (d, *J* = 8.2 Hz, 2H), 3.84 (s, 3H), 3.53 (s, 2H), 2.36 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 171.9, 165.8, 145.6, 143.6, 134.4, 130.2, 129.4, 127.6, 126.1, 125.5, 122.8, 112.8, 51.8, 35.3, 21.3.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₇H₁₆NO₅S: 346.0744; found: 346.0746.

Benzofuran-2(3*H*)-one (3k)^{25a}

Prepared according to the general procedure from benzofuran-2-ylboronic acid, MIDA ester (27 mg). Yield: 14 mg, 100%. White amorphous solid.

IR (solid): 2956, 2926, 1798, 1779, 1616, 1601, 1480, 1465, 1299 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.26–7.19 (m, 2H), 7.06 (t, *J* = 7.5 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 3.66 (s, 2H).

¹³C NMR (CDCl₃, 101 MHz): δ 173.6, 154.2, 128.4, 124.1, 123.6, 122.6, 110.3, 32.5.

5-Fluorobenzofuran-2(3*H*)-one (3l)

Prepared according to the general procedure from (5-fluorobenzofuran-2-yl)boronic acid, MIDA ester (29 mg). Yield: 15 mg, 98%. White amorphous solid.

IR (solid): 3081, 2958, 2926, 2855, 1796, 1634, 1610, 1483, 1400, 1388 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.07–6.82 (m, 3H), 3.69 (s, 2H).

¹³C NMR (CDCl₃, 500 MHz): δ 173.6, 159.4 (d, ¹*J*_{C-F} = 242.5 Hz), 150.6, 124.4 (d, ³*J*_{C-F} = 9.5 Hz), 115.5 (d, ²*J*_{C-F} = 24.3 Hz), 112.2 (d, ²*J*_{C-F} = 25.6 Hz), 111.7 (d, ³*J*_{C-F} = 8.4 Hz), 33.5.

¹⁹F NMR (CDCl₃, 471 MHz): δ -118.2.

HRMS (TOF): *m/z* [M+H]⁺ calcd for C₈H₅FO₂: 153.0352; found: 153.0354.

Oxindole (6)^{25b}

A 10 mL flask was charged with sodium metal (138 mg, 6 mmol, 60 equiv) and naphthalene (385 mg, 3 mmol, 30 equiv) before the addition of DME (5 mL) and the reaction mixture was stirred at room temperature for 30 min to form a blue/green solution. A solution of 1-tosylindolin-2-one (28 mg, 0.1 mmol, 1 equiv) in DME (0.5 mL, 0.2 M) was cooled to -78 °C and the Na-naphthalenide solution was then added dropwise until an orange/red colour persisted (1.5 mL). The solution was then warmed to room temperature and a further 0.5 mL Na-naphthalenide solution was added. The reaction was then quenched with H₂O (2 mL), extracted with EtOAc (5 mL), and washed with brine (5 mL). The organics were then passed through a hydrophobic frit and

concentrated under vacuum before being purified (silica gel, 10-40% EtOAc/petroleum ether) to afford the desired product. Yield: 12 mg, 90%. Beige amorphous solid.

IR (solid): 3161, 1692, 1618, 1469, 1332 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 9.20 (s, 1H), 7.24 (t, *J* = 7.4 Hz, 2H), 7.05 (d, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 7.8 Hz, 1H), 3.57 (s, 2H).

¹³C NMR (CDCl₃, 101 MHz): δ 177.7, 142.1, 127.4, 124.8, 124.1, 121.8, 109.3, 35.8.

Semaxanib

A 25 mL flask was charged with oxindole (133 mg, 1 mmol, 1 equiv) and 3,5-dimethyl-1*H*-pyrrole-2-carbaldehyde (148 mg, 1.2 mmol, 1.2 equiv) before the addition of EtOH (10 mL, 0.5 M). Piperidine (12 μL, 0.01 mmol, 0.01 equiv) was then added and the flask was equipped with a condenser before heating to reflux for 4 h. The reaction mixture was then cooled to room temperature and concentrated under vacuum to afford a red/orange solid. The precipitate was collected by filtration and washed with chloroform to afford the desired product. Yield: 230 mg, 97%. Red/orange amorphous solid.

IR (solid): 3166, 3122, 2917, 2842, 1668, 1617, 1565, 1554, 1539, 1463, 1455, 1340, 1316, 1204 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 13.12 (s, 1H), 8.00 (s, 1H), 7.49 (d, *J* = 7.6 Hz, 1H), 7.40 (s, 1H), 7.13 (td, *J* = 7.6, 1.2 Hz, 1H), 7.05 (td, *J* = 7.6, 1.1 Hz, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 5.98 (d, *J* = 2.5 Hz, 1H), 2.39 (s, 3H), 2.34 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ 169.8, 137.0, 136.9, 132.6, 127.1, 126.6, 125.6, 123.6, 121.5, 117.4, 112.7, 111.8, 109.2, 13.9, 11.6.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₅H₁₅N₂O: 239.1179; found: 239.1177.

Spiro[cyclopropane-1,3'-indolin]-2'-one (8)

An oven dried flask was charged with oxindole (133 mg, 1 mmol, 1 equiv) before the addition of dry DMF (1.25 mL, 0.8 M) and dibromoethane (94 μL, 1.1 mmol, 1.1 equiv). The solution was then cooled to 0 °C before the addition of NaH (60% dispersion in mineral oil, 180 mg, 4.5 mmol, 4.5 equiv) portionwise over 20 min. The reaction mixture was then warmed to room temperature and stirred overnight before being quenched with H₂O (3 mL) and extracted with EtOAc (5 mL). The organics were then washed with H₂O (2 × 5 mL) and brine (2 × 5 mL). The organics were then passed through a hydrophobic frit and concentrated under vacuum before being purified (silica gel, 20-40% EtOAc/petroleum ether) to afford the desired product. Yield: 23 mg, 14%. Red/brown amorphous solid.

IR (solid): 3200, 1701, 1684, 1671, 1627, 1474, 1357 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.34 (s, 1H), 7.19 (t, *J* = 7.7 Hz, 1H), 7.01 (t, *J* = 7.5 Hz, 1H), 6.96 (d, *J* = 7.7 Hz, 1H), 6.83 (d, *J* = 7.4 Hz, 1H), 1.76 (d, *J* = 3.0 Hz, 2H), 1.54 (d, *J* = 2.9 Hz, 2H).

¹³C NMR (CDCl₃, 101 MHz): δ 179.1, 140.6, 131.3, 126.7, 122.0, 118.6, 109.7, 27.4, 19.5.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₀H₁₀NO: 160.0757; found: 160.0753.

Coerulescine

A 5 mL microwave vial equipped with a stirrer bar was charged with spiro[cyclopropane-1,3'-indolin]-2'-one (20 mg, 0.125 mmol, 1 equiv) and MgI₂ (1.74 mg, 6.25 μmol, 5 mol%) before being capped and purged with N₂. THF (0.2 mL, 0.6 M) and trimethyl triazinane (18 μL, 0.125 mmol, 1 equiv) were then added and the reaction mixture was heated to 125 °C in a sandbath for 60 h. The reaction mixture was then cooled to room temperature before being diluted with EtOAc (5 mL) and washed with H₂O (5 mL) and brine (5 mL). The organics were then passed through a hydrophobic frit and concentrated under vacuum before being purified (silica gel, 50% EtOAc/petroleum ether followed by 20% MeOH/DCM) to afford the desired product. Yield: 14 mg, 55%. Pale yellow oil.

IR (solid): 3192, 3060, 2943, 2787, 1707, 1619, 1472, 1336, 1195 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.45 (s, 1H), 7.41 (d, *J* = 7.3 Hz, 1H), 7.19 (td, *J* = 7.7, 1.2 Hz, 1H), 7.04 (td, *J* = 7.6, 1.0 Hz, 1H), 6.89 (d, *J* = 7.7 Hz, 1H), 3.11–3.00 (m, 1H), 2.91 (s, 2H), 2.88–2.74 (m, 1H), 2.49 (s, 3H), 2.41 (ddd, *J* = 12.5, 7.7, 4.7 Hz, 1H), 2.12 (dt, *J* = 12.9, 7.5 Hz, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ 182.7, 140.1, 136.0, 127.8, 123.4, 122.9, 109.5, 66.2, 56.7, 53.6, 41.8, 38.0.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₂H₁₅N₂O: 203.1179; found: 203.1177.

5-Chloroindolin-2-one (9)

To a 10 mL flask charged with sodium metal (83 mg, 3.6 mmol, 60 equiv) and naphthalene (231 mg, 1.8 mmol, 30 equiv) was added DME (5 mL) and the reaction mixture was stirred at room temperature for 30 min to form a blue/green solution. A solution of 5-chloro-1-tosylindolin-2-one (20 mg, 0.06 mmol, 1 equiv) in DME (0.3 mL, 0.2 M) was cooled to -78 °C and the Na-naphthalenide solution was then added dropwise until an orange/red colour persisted (1.5 mL). The solution was then warmed to room temperature and a further 0.5 mL Na-naphthalenide solution was added. The reaction was then quenched with H₂O (2 mL), extracted with EtOAc (5 mL), and washed with brine (5 mL). The organics were then passed through a hydrophobic frit and concentrated under vacuum before being purified (silica gel, 10–40% EtOAc/petroleum ether) to afford the desired product. Yield: 8 mg, 80%. Off-white amorphous solid.

IR (solid): 3159, 3047, 2960, 2926, 2855, 1699, 1621, 1478, 1379, 1316 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 8.07 (s, 1H), 7.20 (d, *J* = 11.5 Hz, 2H), 6.80 (d, *J* = 8.1 Hz, 1H), 3.54 (s, 2H).

¹³C NMR (CDCl₃, 101 MHz): δ 175.5, 139.8, 127.0, 126.7, 125.9, 124.1, 109.4, 35.0.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₈H₇ClNO: 168.0211; found: 168.0207.

Phenyl 5-chloro-2-oxoindoline-1-carboxylate (10)

Step 1: Phenyl 5-chloro-2-((phenoxycarbonyl)oxy)-1*H*-indole-1-carboxylate.

To a flask charged with 5-chloro-2-oxindole (1 g, 6 mmol, 1 equiv) was added 20 mL dry THF followed by triethylamine (1.75 mL, 12.6 mmol, 2.1 equiv). The reaction mixture was cooled to 0 °C before the dropwise addition of phenyl chloroformate (1.6 mL, 13.2 mmol, 2.2 equiv). The mixture was stirred at 0 °C for 1 h. The resulting precipitate was then removed by filtration and the filter cake was washed with THF (2×20 mL). The filtrate was then concentrated under vacuum to obtain a pink solid which was stirred in 20 mL H₂O to form an emulsion. This was then filtered, washed with H₂O (2×20 mL), and dried by drawing air through the filter cake to afford the desired product phenyl 5-chloro-2-((phenoxycarbonyl)oxy)-1*H*-indole-1-carboxylate. Yield: 2.4 g (crude weight). White solid. The product was used directly in the next step without further purification.

Step 2

A solution of phenyl 5-chloro-2-((phenoxycarbonyl)oxy)-1*H*-indole-1-carboxylate (1.11 g, 2.75 mmol, 1 equiv) in dry DMF (10 mL) was cooled to 0 °C, followed by the portionwise addition of ammonium carbonate powder (300 mg, 3.16 mmol, 1.15 equiv). The resulting solution was stirred for 1 h at 0 °C. Upon consumption of the starting material the pale yellow solution was then poured into 30 mL ice water to provide a white precipitate. The suspension was then stirred for 30 min before being filtered, washed with H₂O (2×10 mL) and dried by pulling air through the filter cake to afford the desired product **10**. Yield: 585 mg, 73% over two steps. White amorphous solid.

IR (solid): 3137, 3060, 2956, 2932, 1770, 1737, 1595, 1478 cm⁻¹.

¹H NMR (CDCl₃, 500 MHz): δ 7.92 (d, *J* = 8.7 Hz, 1H), 7.47 (t, *J* = 7.9 Hz, 2H), 7.37–7.29 (m, 5H), 3.80 (s, 2H).

¹³C NMR (CDCl₃, 126 MHz): δ 171.5, 150.0, 149.4, 138.9, 130.5, 129.7, 128.5, 126.6, 125.0, 124.6, 121.5, 116.7, 36.3.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₅H₁₁ClNO₃: 288.0422; found: 288.0423.

Tenidap

Step 1: Phenyl (*E*)-5-chloro-3-(hydroxy(thiophen-2-yl)methylene)-2-oxoindoline-1-carboxylate (**11**). To a 50 mL flask charged with phenyl 5-chloro-2-oxoindoline-1-carboxylate (100 mg, 0.35 mmol, 1 equiv) and 4-dimethylaminopyridine 10.7 g (74 mg, 0.735 mmol, 2.1 equiv) was added anhydrous DMF (1.4 mL, 0.25 M), and cooled to 0 °C. A solution of thiophene-2-carbonyl chloride (56 mg, 0.385 mmol, 1.1 equiv) in dry DMF (0.6 mL) was then added dropwise and the resulting suspension was stirred at 0 °C until consumption of the starting material (approx. 1 h). The solution was then poured into 3 mL ice water, acidified to pH 2–3 with concentrated hydrochloric acid and stirred for 3 h. The resulting precipitate was then filtrated, washed with H₂O (2×5 mL), and dried by drawing air through the filter cake to afford the desired product **11**. Yield: 111 mg (crude weight). Pale yellow solid. The product was used directly in the next step without further purification.

Step 2: To a solution of phenyl (*E*)-5-chloro-3-(hydroxy(thiophen-2-yl)methylene)-2-oxoindoline-1-carboxylate (12 mg, 0.03 mmol, 1 equiv) in dry DMF (0.2 mL, 0.15 M) was added ammonium carbonate powder (3 mg, 0.03 mmol, 1 equiv). The resulting solution was then stirred at 80 °C for 4 h. The reaction mixture was then cooled to room temperature before being diluted with EtOAc (5 mL) and washed with H₂O (5 mL). The organics were then passed through a hydrophobic frit and concentrated under vacuum before being purified (silica gel, 0–100% MeOH/CH₂Cl₂) to afford the desired product. Yield: 9 mg, 75% over two steps. Yellow amorphous solid.

IR (solid): 3330, 2254, 1694, 1627, 1595, 1571, 1457, 1424 cm⁻¹.

¹H NMR (DMSO, 500 MHz): δ 9.35 (s, 1H), 8.59 (d, *J* = 3.3 Hz, 1H), 8.16 (d, *J* = 1.8 Hz, 1H), 8.01 (d, *J* = 8.5 Hz, 1H), 7.59 (d, *J* = 4.9 Hz, 1H), 7.11 – 7.04 (m, 2H), 6.79 (dd, *J* = 8.5, 2.3 Hz, 1H).

¹³C NMR (DMSO, 101 MHz): δ 176.8, 165.7, 154.7, 149.1, 132.0, 130.1, 129.5, 129.1, 126.9, 126.0, 118.3, 117.3, 113.9, 94.3.

HRMS (NSI): *m/z* [M+H]⁺ calcd for C₁₄H₁₀ClN₂O₃S: 321.0095; found: 321.0099.

Acknowledgment

We thank the Carnegie Trust for a PhD studentship (CPS) and the EPSRC UK National Mass Spectrometry Facility at Swansea University for analyses.

Supporting Information

Optimization data, and ¹H and ¹³C NMR spectra for all new compounds.

References

- (1) (a) Galliford, C. V.; Scheidt, K. A. *Angew. Chem. Int. Ed.* **2007**, *46*, 8748. (b) Zhou, F.; Liu, Y.-L.; Zhou, J. *Adv. Synth. Catal.* **2010**, *352*, 1381.
- (2) For representative examples see: (a) Carlo, F. J. *J. Am. Chem. Soc.* **1944**, *66*, 1420. (b) Motoyama, Y.; Kamo, K.; Nagashima, H. *Org. Lett.* **2009**, *11*, 1345.
- (3) For representative examples see: (a) Hennessy, E. J.; Buchwald, S. L. *J. Am. Chem. Soc.* **2003**, *125*, 12084. (b) Ackermann, L.; Vicente, R.; Hofmann, N. *Org. Lett.* **2009**, *11*, 4274. (c) Beyer, A.; Buendia, J.; Bolm, C. *Org. Lett.* **2012**, *14*, 3948. (d) Liu, C.; Liu, D.; Zhang, W.; Zhou, L.; Lei, A. *Org. Lett.* **2013**, *15*, 6166.
- (4) For examples using enzymatic catalysis, see: (a) Corbett, M. D.; Chipko, B. R. *Biochem. J.* **1979**, *183*, 269. For examples proceeding via 3-haloindoles, see: (b) Marfat, A.; Carta, M. P.; *Tetrahedron Lett.* **1987**, *28*, 4027. (c) Yousuf, Z.; Richards, A. K.; Dwyer, A. N.; Linclau, B.; Harrowven, D. C. *Org. Biomol. Chem.* **2015**, *13*, 10532.
- (5) Parrick, J.; Yahya, A.; Ijaz, A. S.; Yizun, J. *J. Chem. Soc., Perkin Trans. 1* **1989**, *11*, 2009.

- (6) For a recent example of oxindole synthesis *via* 2-oxyindoles see: Cao, T.; Linton, E. C.; Deitch, J.; Berritt, S.; Kozlowski, M. C. *J. Org. Chem.* **2012**, *77*, 11034.
- (7) Seath, C. P.; Wilson, K.; Campbell, A.; Mowat, J. M.; Watson, A. J. B. *Chem. Commun.* accepted.
- (8) For recent reviews, see: (a) Gillis, E. P.; Burke, M. D. *Aldrichim. Acta* **2009**, *42*, 17. (b) Li, J.; Grillo, A. S.; Burke, M. D. *Acc. Chem. Res.* **2015**, *48*, 2297.
- (9) (a) Tobisu, M.; Fujihara, H.; Koh, K.; Chatani, N. *J. Org. Chem.* **2010**, *75*, 4841. (b) Homer, J. A.; Sperry, J. *Tetrahedron Lett.* **2014**, *55*, 5798.
- (10) Knapp, D. M.; Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* **2009**, *131*, 6961.
- (11) Brown, H. C. *Organic Synthesis via Organoboranes*, Wiley Interscience, New York, 1975.
- (12) Initial screening of reaction conditions were based on a report from Hutton: Churches, Q. I.; Hooper, J. F.; Hutton, C. A. *J. Org. Chem.* **2015**, *80*, 5428.
- (13) Molander has reported the oxidation of four different 2-heterocyclic organotrifluoroborates: Molander, G. A.; Cavalcanti, L. N. *J. Org. Chem.* **2011**, *76*, 623.
- (14) (a) Fyfe, J. W. B.; Seath, C. P.; Watson, A. J. B. *Angew. Chem. Int. Ed.* **2014**, *53*, 12077. (b) Molloy, J. J.; Law, R. P.; Fyfe, J. W. B.; Seath, C. P.; Hirst, D. J.; Watson, A. J. B. *Org. Biomol. Chem.* **2015**, *13*, 3093. (c) Castagna, D.; Duffy, E. L.; Semann, D.; Young, L. C.; Pritchard, J. M.; MacDonald, S. J. F.; Budd, D. C.; Jamieson, C.; Watson, A. J. B. *Med. Chem. Commun.* **2015**, *6*, 1149. (d) Seath, C. P.; Fyfe, J. W. B.; Molloy, J. J.; Watson, A. J. B. *Angew. Chem. Int. Ed.* **2015**, *54*, 9976. (e) Muir, C. W.; Vantourout, J. C.; Isidro-Llobet, A.; Macdonald S. J. F.; Watson, A. J. B. *Org. Lett.* **2015**, *17*, 6030. (f) Castagna, D.; Budd, D. C.; Macdonald, S. J. F.; Jamieson, C.; Watson, A. J. B. *J. Med. Chem.* DOI: 10.1021/acs.jmedchem.5b01599.
- (15) Mendel, D. B.; Laird, D.; Smolich, B. D.; Blake, R. A.; Liang, C.; Hannah, A. L.; Shaheen, R. M.; Ellis, L. M.; Weitman, S.; Shawver, L. K.; Cherrington, J. M. *Anti-Cancer Drug Design* **2000**, *15*, 29.
- (16) (a) Clift, M. D.; Silverman, R. B. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3122. (b) Carvalho, L. C. R.; Ribeiro, D.; Seixas, R. S. G. R.; Silva, A. M. S.; Nave, M.; Martins, A. C.; Erhardt, S.; Fernandes, E.; Cabrita, E. J.; M. Marques, M. B. *RSC Adv.* **2015**, *5*, 49098.
- (17) (a) Jones, K.; McCarthy, C. *Tetrahedron Lett.* **1989**, *30*, 2657. (b) Muira, T.; Ito, Y.; Murakami, M. *Chem. Lett.* **2009**, *4*, 328. (c) Qiao, X.-C.; Zhu, S.-F.; Zhou, Q.-L. *Tetrahedron: Asymm.* **2009**, *20*, 1254. (d) Yang, L.-Q.; Wang, K.-B.; Li, C.-Y. *Eur. J. Org. Chem.* **2013**, *14*, 2775. (e) Deng, J.-C.; Chen, W.-Y.; Zhu, C. Chuang, S.-C. *Adv. Synth. Catal.* **2015**, *357*, 1453.
- (18) Anker, T.; Hilmersson, G. *Org. Lett.* **2009**, *11*, 503.
- (19) Bergmeier, S. B.; Seth, P. P. *Tetrahedron Lett.* **1999**, *40*, 6181.
- (20) Changa, M.-Y.; Paib, C.-L.; Kunga Y.-H. *Tetrahedron Lett.* **2005**, *46*, 8463. (b) Kulkarni, M. G.; Dhondge, A. P.; Chavhan, S. W.; Borhade, A. S.; Shaikh, Y. B.; Bihade, D. R.; Desai, M. P.; Dhattrak, N. R. *Beilstein J. Org. Chem.* **2010**, *6*, 876.
- (21) O'Donnell, A.; Padhani, A.; Hayes, C.; Kakkar, A. J.; Leach, M.; Trigo, J. M.; Scurr, M.; Raynaud, F.; Phillips, S.; Aherne, W.; Hardcastle, A.; Workman, P. Hannah, A.; Judson, I. *Br. J. Cancer* **2005**, *93*, 876.
- (22) Alper, P. B.; Meyers, C.; Lerchner, A.; Siegel, D. R.; Meyers, C.; Carreira, E. M. *Angew. Chem. Int. Ed.* **1999**, *38*, 3186.
- (23) Moore, P. F.; Larson, D. L.; Otterness, I. G.; Weissman, A.; Kadin, S. B.; Sweeney, F. J.; Eskra, J. D.; Nagahisa, A.; Sakakibara, M.; Carty, T. J. *Inflamm. Res.* **1996**, *45*, 54.
- (24) Armarego, W. L. F.; Chai, C. *Purification of Laboratory Chemicals*, 7th ed., Elsevier, Oxford, 2013.
- (25) Material commercially available from Sigma Aldrich (a) CAS: 553-86-6, Catalogue no: 124591 (b) CAS: 59-48-3, Catalogue no: 09808.

Synthesis of Oxindoles and Benzofuranones via Oxidation of 2-Heterocyclic BMIDAs

Ciaran P. Seath, James W. B. Fyfe, John J. Molloy, and Allan J. B. Watson*

Department of Pure and Applied Chemistry, WestCHEM, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow, G1 1XL, UK.

Contents

1. General
2. General Experimental Procedures
3. Compound Characterization Data
 - 4.1 Intermediates
 - 4.2 Products from Scheme 3
 - 4.3 Products from Scheme 4
 - 4.4 Products from Schemes 5 and 6
4. References
5. NMR spectra for intermediates and products

1. General

All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Purification was carried out according to standard laboratory methods.¹

1.1 Purification of Solvents

DMF was dried by heating to reflux over previously activated 4 Å molecular sieves and distilling under vacuum before being purged with, and stored under N₂ in a septum-sealed oven-dried flask over previously activated 4 Å molecular sieves. Acetone, MeOH, CH₂Cl₂, Et₂O, EtOAc, MeCN, and petroleum ether 40-60° for purification purposes were used as obtained from suppliers without further purification.

1.3 Experimental Details

Reactions were carried out using conventional glassware (preparation of intermediates) or in capped 5 mL microwave vials. The glassware was oven-dried (150 °C) and purged with N₂ before use. Purging refers to a vacuum/nitrogen-refilling procedure. Room temperature was generally *ca.* 18 °C. Reactions were carried out at elevated temperatures using a temperature-regulated hotplate/stirrer.

1.4 Purification of Products

Thin layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analyzed under 254 nm UV light or developed using potassium permanganate solution. Normal phase flash chromatography was carried out using ZEOprep 60 HYD 40-63 µm silica gel.

1.5 Analysis of Products

Fourier Transformed Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 machine. ¹⁹F NMR spectra were obtained on a Bruker AV 400 spectrometer at 376 MHz. ¹¹B NMR spectra were obtained on a Bruker AV 400 spectrometer at 128 MHz. ¹H and ¹³C NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 125 MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz with CDCl₃ referenced at 7.26 (¹H) and 77.0 ppm (¹³C) and DMSO-d₆ referenced at 2.50 (¹H) and 39.5 (¹³C). ¹¹B NMR spectra are referenced to BF₃•Et₂O. High-resolution mass spectra were obtained through analysis at the EPSRC UK National Mass Spectrometry Facility at Swansea University. Reversed phase HPLC data was obtained on an Agilent 1200 series HPLC using a Machery-Nagel Nucleodur C18 column. Analysis was performed using a gradient method, eluting with 5–80% MeCN/H₂O over 16 minutes at a flow rate of 2 mL/min. Samples for HPLC analysis were prepared through the addition of 2 mL of caffeine standard in MeCN to the completed reaction mixture. The resulting solution was then stirred before the removal of a 200 µL aliquot. The aliquot was diluted to 1 mL with MeCN. A 200 µL aliquot of the diluted solution was then filtered through cotton wool and further diluted with 800 µL MeCN and 500 µL H₂O for HPLC analysis against established conversion factors.

2. Optimization of Hydrolysis/Oxidation procedure

2.1 General procedure for optimization reactions.

A 10 mL microwave vial was charged with *N*-tosylindole-2-BMIDA (43 mg, 0.1 mmol, 1 equiv) before the addition of **solvent** (0.4 mL, 0.25 M) and **base** (**x equiv**). To the resulting solution was added **oxidant** (**x equiv**). The reaction mixture was stirred at **X °C** for **X h** before being quenched with sodium metabisulfite (10 mg). The reaction mixtures were then analyzed by reverse phase HPLC against established conversion factors.

2.2 H₂O₂ optimization

Carried out according to the general procedure using 30% w/v H₂O₂ (0.2 mL, 2.5 mmol, 25 equiv) for 1 hr.

Entry	Base (vol/mass)	Base equiv	Solvent	Temp (°C)	Conversion %
1	aq. NaOH (0.3 M, 1 mL)	3	MeCN	rt	0
2	aq. NaOH (0.3 M, 1.67 mL)	5	MeCN	rt	0
3	aq. NaOH (0.3 M, 3.3 mL)	10	MeCN	rt	0
4	aq. NaOH (0.3 M, 1 mL)	3	MeCN	50	0
5	aq. NaOH (0.3 M, 1.67 mL)	5	MeCN	50	0
6	aq. NaOH (0.3 M, 3.3 mL)	10	MeCN	50	0
7	K ₃ PO ₄ (64 mg)	3	THF	rt	0
8	K ₃ PO ₄ (64 mg)	3	MeCN	rt	0
9	K ₃ PO ₄ (64 mg)	3	THF	50	0
10	K ₃ PO ₄ (64 mg)	3	MeCN	50	0
11	K ₃ PO ₄ (64 mg)	3	THF	rt	0
12	K ₃ PO ₄ (64 mg)	3	MeCN	rt	0
13	K ₃ PO ₄ (64 mg)	3	THF	50	0
14	K ₃ PO ₄ (64 mg)	3	MeCN	50	0
15	K ₃ PO ₄ (64 mg)	3	THF	rt	0
16	K ₃ PO ₄ (64 mg)	3	MeCN	rt	0
17	K ₃ PO ₄ (64 mg)	3	THF	50	0
18	K ₃ PO ₄ (64 mg)	3	MeCN	50	0

2.3 Oxone optimization

Carried out according to the general procedure for 24 hr.

Entry	Oxone [®] equiv (mass)	K ₃ PO ₄ equiv (mass)	Temperature (°C)	Solvent	Conversion %
1	10 (307 mg)*	3 (64 mg)	50	THF	0
2	10 (307 mg)*	3 (64 mg)	60	THF	0
3	10 (307 mg)*	3 (64 mg)	70	THF	0
4	2.5 (77 mg)	3 (64 mg)	60	MeCN	0
5	2.5 (77 mg)	3 (64 mg)	70	MeCN	0
6	2.5 (77 mg)	-	60	MeCN	15
7	2.5 (77 mg)	-	70	MeCN	16
8	10 (307 mg)*	-	50	THF	11
9	10 (307 mg)*	-	60	THF	11
10	10 (307 mg)*	-	70	THF	4

* Oxone was added to the reaction as a solution in 2 mL H₂O

4. Compound characterization data

Synthesis of starting materials.

Compounds **1a**, **b**, **c**, **f**, **g**, **h**, **i** and **l** were synthesized according to ref 7. Compounds **1d** and **j** were purchased from commercial suppliers and used as received.

Synthesis of (5-chloro-1-tosyl-1H-indol-2-yl)boronic acid, MIDA ester **1e**

To an oven dried 50 mL flask was added *N*-(2-iodo-4-chlorophenyl)-4-methylbenzenesulfonamide (1.02 g, 2.5 mmol, 1 equiv), ethynyl boronic acid, MIDA ester (540 mg, 3 mmol, 1.2 equiv), Pd(PPh₃)₂Cl₂ (35 mg, 0.05 mmol, 2 mol%), CuI (48 mg, 0.25 mmol, 10 mol%), Cu(OAc)₂ (136 mg, 0.75 mmol, 30 mol%), and K₃PO₄ (530 mg, 2.5 mmol, 1 equiv). The flask was then sealed and purged with N₂ before addition of DMF (20 mL, 0.125 M). The reaction mixture was then heated to 30 °C for 4 h before being heated to 55 °C for a further 14 h. The reaction mixture was allowed to cool to room temperature before the solution was then dried and concentrated under reduced pressure before being diluted with EtOAc (10 mL) and washed with water (2 × 20 mL) and brine (2 × 20 mL). The organics were then dried and concentrated under reduced pressure to give a yellow oil, which was purified by flash chromatography (silica gel, 40-70% EtOAc/petroleum ether) to afford the title compound as an off-white solid (790 mg, 69%).

ν_{max} (solid): 2972, 1763, 1599, 1526, 1448, 1340, 1295 cm⁻¹.

¹H NMR (DMSO-*d*₆, 400 MHz): δ 8.12 (d, *J* = 9.0 Hz, 1H), 7.90 (d, *J* = 8.3 Hz, 2H), 7.74 (d, *J* = 1.7 Hz, 1H), 7.44 – 7.32 (m, 3H), 7.05 (s, 1H), 4.47 (d, *J* = 17.5 Hz, 2H), 4.23 (d, *J* = 17.5 Hz, 2H), 2.95 (s, 3H), 2.33 (s, 3H).

¹³C NMR (DMSO-*d*₆, 101 MHz): δ 169.1, 145.5, 136.9, 134.7, 131.1, 130.0, 128.0, 126.6, 125.0, 120.9, 120.8, 115.8, 64.3, 49.4, 21.0. Carbon bearing boron not observed.

¹¹B NMR (DMSO-*d*₆, 128 MHz): δ 10.38.

HRMS: exact mass calculated for [M+H]⁺ (C₂₀H₁₉ClN₂O₆SB) requires *m/z* 461.0749, found *m/z* 461.0766.

Synthesis of (5-methoxy-1-tosyl-1H-indol-2-yl)boronic acid, MIDA ester **1g**

To an oven dried 5 mL microwave vessel was added *N*-(2-iodo-4-methoxyphenyl)-4-methylbenzenesulfonamide (202 mg, 0.5 mmol, 1 equiv), ethynyl boronic acid, MIDA ester (109 mg, 0.6 mmol, 1.2 equiv), Pd(PPh₃)₂Cl₂ (7 mg, 0.01 mmol, 2 mol%), CuI (9.5 mg, 0.05 mmol, 10 mol%), Cu(OAc)₂ (27.2 mg, 0.15 mmol, 30 mol%), and K₃PO₄ (106 mg, 0.5 mmol, 1 equiv). The vessel was then capped and purged with N₂ before addition of DMF (4 mL, 0.125 M). The reaction mixture was then heated to 30 °C in a sand bath for 4 h before being heated to 55 °C for a further 14 h. The vessel was allowed to cool to room temperature, vented, and decapped. The solution was then dried and concentrated under reduced pressure before being diluted with EtOAc (20 mL) and washed with water (2 × 40 mL) and brine (2 × 40 mL). The organics were then dried and concentrated under reduced pressure to give a yellow oil, which was purified by flash chromatography (silica gel, 40-70% EtOAc/petroleum ether) to afford the title compound as a white solid (150 mg, 66%).

ν_{max} (solid): 2960, 2926, 2855, 1763, 1617, 1532, 1464, 1340, 1299 cm^{-1} .

^1H NMR (DMSO- d_6 , 400 MHz): δ 8.01 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 2.5 Hz, 1H), 7.00–6.94 (m, 2H), 4.46 (d, J = 17.5 Hz, 2H), 4.23 (d, J = 17.4 Hz, 2H), 3.76 (s, 3H), 2.96 (s, 3H), 2.33 (s, 3H).

^{13}C NMR (DMSO- d_6 , 101 MHz): δ 168.9, 155.8, 144.9, 134.8, 132.9, 130.5, 129.6, 126.3, 121.6, 114.9, 114.0, 103.3, 64.0, 55.2, 49.2, 20.8. Carbon bearing boron not observed.

^{11}B NMR (DMSO- d_6 , 128 MHz): δ 10.33.

HRMS: exact mass calculated for $[\text{M}+\text{NH}_4]^+$ ($\text{C}_{21}\text{H}_{25}\text{BN}_3\text{O}_7\text{S}$) requires m/z 474.1505, found m/z 474.1497.

5. References

1. W. L. F. Armarego, C. Chai, *Purification of Laboratory Chemicals*, 7th ed., Elsevier, Oxford, 2013.

6. NMR and HRMS spectra for intermediates and products

^1H NMR of **1e**

^{13}C NMR of **1e**

¹¹B NMR of 1e

¹H NMR of 1g

^{13}C NMR of 1g

^{11}B NMR of 1g

¹H NMR of 3a

¹³C NMR of 3a

¹H NMR of 3b

¹³C NMR of 3b

¹H NMR of 3c

¹³C NMR of 3c

¹H NMR of 3d

¹³C NMR of 3d

^{19}F NMR of **3d**

^1H NMR of **3e**

¹³C NMR of 3e

¹H NMR of 3f

¹³C NMR of 3f

¹H NMR of 3g

¹³C NMR of 3g

¹H NMR of 3h

^{13}C NMR of 3h

^{19}F NMR of 3h

Chemical structure of **3i** is shown. The ¹H NMR spectrum (CDCl₃) displays peaks corresponding to the structure, with chemical shifts (δ) and integration values indicated.

Chemical shifts (δ) listed: 8.09, 8.09, 8.09, 8.07, 8.07, 8.07, 8.03, 8.02, 8.01, 8.01, 7.92, 7.92, 7.37, 7.35, 3.94, 3.62, 2.45.

Integration values: 1.07, 3.14, 1.00, 2.30, 3.30, 2.14.

Chemical shifts (ppm): 171.85, 165.78, 145.59, 143.61, 134.39, 130.22, 128.44, 128.40, 127.60, 126.85, 125.59, 122.82, 112.83, 51.77, 35.30, 21.25.

Crude ^1H NMR of 3j

^1H NMR of 3k

¹³C NMR of 3k

¹H NMR of 3l

^{13}C NMR of 3l

^{19}F NMR of 3l

¹H NMR of 6

¹³C NMR of 6

¹H NMR of semaxanib

¹³C NMR of semaxanib

¹H NMR of 8

¹³C NMR of 8

¹H NMR of (±) coerulescine

¹³C NMR of (±) coerulescine

¹H NMR of 9

¹³C NMR of 9

¹H NMR of 10

¹³C NMR of 10

¹H NMR of tenidap

¹³C NMR of tenidap